SFDA Halts Sales Of Buflomedil APIs And Drugs
This article was originally published in PharmAsia News
Executive Summary
China’s State FDA ordered a nationwide halt to the production, sale and use of buflomedil APIs and drugs, revoked all relevant approval, and requested that regional FDAs destroy any available stock.